Uniseed
Staff House Rd, St Lucia, Queensland, 4067, Australia
Overview
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff of these organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund. A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011. With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position. On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million). Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network. The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
- Total investments
- 34
- Lead investments
- 14
- Investments · 12mo
- 5
- Active investors
- 8
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- PlasmaLeap
Participated · Series A · Mar 2026
PlasmaLeap designs, manufactures and sells modular plasma reactors that synthesize ammonia and nitric acid from air, water and renewable power, eliminating the fossil-fuel inputs and heavy transport normally required for nitrogen fertiliser production. Spun out of the University of Sydney, the company targets on-farm or local hub installations that cut growers’ input costs, lower supply-chain risk and slash CO₂ emissions from fertiliser manufacturing, transport and field losses—an impact area that accounts for roughly 2.5 % of global industrial emissions. Its platform is also being engineered to make e-fuels, synthetic hydrocarbons and other industrial chemicals, opening pathways to decarbonise hard-to-abate sectors like energy and transport. PlasmaLeap is currently progressing first-of-a-kind fertiliser hubs in New South Wales and Tasmania and expanding field trials to validate commercial performance. Management expects the solution to generate high-quality carbon credits and improve national food security by shielding farmers from global price shocks. Financially, the company has just secured almost A$30 million (US$20 million) in Series A capital to fund these deployments and further R&D, adding to earlier grants such as support from the Gates Foundation.
- Ferronova
Led · Series A · Dec 2025
Ferronova is an Adelaide-based medical technology company developing a super-paramagnetic iron oxide nanoparticle tracer system designed to improve image-guided cancer surgery. The nanoparticles bind to lymph-node cells, allowing surgeons to identify tissue that may harbour metastasised cancer and thereby reduce post-operative recurrence. The company is running a 60-patient, two-year clinical trial on stomach and oesophageal cancers at leading Australian centres, having enrolled 54 patients with completion expected in early 2026. Management plans to extend research to the United States over the next two years as it moves toward regulatory approval and commercial launch. Roughly 1.8 million people are diagnosed with stomach and oesophageal cancers annually, underscoring the market need the firm targets. Ferronova has raised a cumulative $17.5 million in Series A funding, giving it capital to complete trials and pursue commercialisation. Its investor base includes Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian Venture Partners, Renew Pharmaceuticals (UltraGreen.ai), several universities, and health-focused funds. The company’s mission is to enhance surgical precision and improve survival rates in complex, early-stage cancers.
- VeriQuantix
Led · Seed · Oct 2025
VeriQuantix is an early-stage quantum cyber-security company commercialising patented technology that creates two identical photons, keeps one locally and sends the other through a fibre-optic link to detect any interference and thereby confirm data integrity. The system will ship first as hardware, with accompanying software that analyses wavelength changes to identify specific attacks such as data siphoning for future decryption. Invented by Dr Marcelo de Almeida, Professor Andrew White, Dr Till Weinhold and Dr Michael Harvey, the technology holds a 2022 provisional patent that management cites as a key competitive moat. With the newly raised capital, the team is building a demonstration unit and aims to validate performance on a commercial network within 12 months. The roadmap then calls for a rack-mount product for data-centre deployment the following year, followed by miniaturisation and potential licensing to large global equipment vendors. CEO Paul Butler, a 25-year startup veteran, is leading the push toward these milestones. The company is pre-revenue and fully focused on R&D and prototype development.
- Ena Respiratory
Participated · Series B · Oct 2025
Ena Respiratory is a clinical-stage pharmaceutical company focused on combating respiratory viral infections by amplifying the body’s innate immune response. Its lead candidate, INNA-051, is formulated as a convenient once-a-week nasal dry-powder designed to reduce the impact of viral respiratory infections and prevent severe complications in high-risk groups such as the elderly, patients with chronic conditions, and individuals with occupational exposure. The company’s technology centers on locally priming airway mucosa to enhance first-line immune defenses against invading pathogens. Recent financing underscores investor confidence in the potential of INNA-051 as it moves into Phase II clinical trials. With the new funds, Ena Respiratory plans to advance clinical development and generate data that could support broader commercialization or partnership opportunities. Although still pre-revenue, the company’s progress positions it to address significant unmet medical need in antiviral prophylaxis.
- Lucia Bio
Participated · Seed · Sep 2025
Lucia Bio is a Queensland biotech joint venture between the UK’s Molecule to Medicine and the University of Queensland’s QEDDI. The company develops Syk inhibitors targeting autoimmune diseases and neuroinflammation, with lead assets QED-701 and QED-121. It recently topped up its seed round with an additional $2M, bringing total capital raised to $3M. The UniQuest Extension Fund and Uniseed-managed funds each contributed $1M to the extension. The article does not provide operating metrics, a valuation, or details of other financing instruments for Lucia Bio.